Zacks Investment Research cut shares of Cellectis S.A. (NASDAQ:CLLS) from a buy rating to a hold rating in a research note released on Thursday morning.
According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “
A number of other equities research analysts have also recently commented on CLLS. BidaskClub cut shares of Cellectis from a buy rating to a hold rating in a report on Tuesday, July 25th. Jefferies Group LLC set a $47.00 price target on shares of Cellectis and gave the stock a buy rating in a report on Friday, August 25th. Wells Fargo & Company restated an outperform rating and issued a $40.00 price target (up from $33.00) on shares of Cellectis in a report on Tuesday, September 5th. SunTrust Banks, Inc. cut shares of Cellectis from a buy rating to a hold rating and reduced their price target for the stock from $35.00 to $20.00 in a report on Tuesday, September 5th. Finally, Nomura reduced their price target on shares of Cellectis from $49.00 to $43.00 and set a buy rating for the company in a report on Wednesday, September 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Cellectis currently has a consensus rating of Buy and an average target price of $39.50.
ILLEGAL ACTIVITY WARNING: “Cellectis S.A. (CLLS) Downgraded by Zacks Investment Research” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://sportsperspectives.com/2017/11/19/cellectis-s-a-clls-downgraded-by-zacks-investment-research.html.
Several hedge funds and other institutional investors have recently modified their holdings of the company. KBC Group NV acquired a new position in shares of Cellectis during the third quarter valued at about $366,000. Wells Fargo & Company MN grew its holdings in shares of Cellectis by 77.8% during the third quarter. Wells Fargo & Company MN now owns 16,983 shares of the biotechnology company’s stock valued at $483,000 after buying an additional 7,433 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Cellectis during the third quarter valued at about $517,000. Sphera Funds Management LTD. grew its holdings in shares of Cellectis by 71.1% during the third quarter. Sphera Funds Management LTD. now owns 348,736 shares of the biotechnology company’s stock valued at $9,922,000 after buying an additional 144,972 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its holdings in shares of Cellectis by 1,501.1% during the third quarter. Advisors Asset Management Inc. now owns 22,592 shares of the biotechnology company’s stock valued at $643,000 after buying an additional 21,181 shares during the last quarter. Hedge funds and other institutional investors own 14.88% of the company’s stock.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.